Rexahn Pharmaceuticals Engages Catalyst Financial Resources

ROCKVILLE, Md.--(BUSINESS WIRE)--

Rexahn Pharmaceuticals, (OTCBB: RXHN) a clinical stage biopharmaceutical company, today announced that it has engaged Catalyst Financial Resources to execute a comprehensive investor awareness campaign aimed at enhancing shareholder value.

Catalyst Financial Resources will initiate a program that includes participation in various investor conferences, institutional targeting and equity research coverage, to help promote the visibility of Rexahn Pharmaceuticals in the financial marketplace. The engagement is expected to include extensive use of Catalyst Financial Resources' proprietary process for creating, managing and developing institutional exposure to under-followed small- and micro-cap companies.

Commenting on today's news, Dr. Chang Ahn, Chairman and Chief Executive Officer of Rexahn said, "Rexahn has made substantial progress in its clinical development pipeline over the past year. As a result, awareness of the Company's story has grown among both the investor and biopharmaceutical communities. With three potential Phase II trials planned for this year, the timing is perfect to begin to heighten, even further, our investor outreach. We believe that Catalyst Financial Resources will be a key contributor to this effort."

About Rexahn Pharmaceuticals

Rexahn is a clinical stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer, central nervous system disorders, and other unmet medical needs. "Saving Lives Through Innovation," the Company's motto, represents the use of scientific innovation to develop therapies in treating various disease states. Rexahn currently has a number of drug candidates in clinical development for cancer, CNS related disorders, and sexual dysfunction. For further details on the Company and its products please visit the Company's website at www.rexahn.com.

About Catalyst Financial Resources

Catalyst Financial Resources, LLC is an investor awareness firm helping small- and micro-cap companies gain credible exposure in the financial community. Employing the "Catalyst System", we augment a firm's existing investor relations activities and assist in achieving appropriate valuation in the marketplace. The Catalyst System was born out of an intense commitment to the small-cap, under-followed market and the need to forge a new standard on Wall Street. Founded in 2002 by Marc Robins, CFA, Catalyst Financial Resources has a proven track record of meeting the needs of both the management and the shareholders of small-cap companies. Mr. Robins also founded RedChip Review in 1993 and has been a regular columnist in Forbes magazine.

Source: Rexahn Pharmaceuticals